Supplementary Figure S4 from Glycoprotein Mucin 13 Expression as a Theranostic Target in Colorectal Cancer
Le résumé fourni par la source
Supplementary Figure S4. Single dose 161Tb radiopharmaceutical therapy studies in CDX mouse models of CRC. Single dose therapy studies were performed in mice bearing T84 xenografts injected with 5.92 MBq (160 μCi) of [161Tb]Tb-DOTA-C14 (A, C, E) and in mice bearing SNU-C4 xenografts with either 3.70 or 7.40 MBq (100 or 200 μCi, respectively) of [161Tb]Tb-DOTA-C14 (B, D, F). A, B. Overall health status throughout the studies was monitored as a function of weight change. C, D. Tumor volume was measured over time to determine antitumor activity of 161Tb-labeled C14. Data are presented as mean values ± SEM. # One-way ANOVA with Dunnett's multiple comparisons test vs. [161Tb]Tb-DOTA-C14 160 μCi group (C), ¶ Unpaired Student’s t test, # One-way ANOVA with Dunnett's multiple comparisons test (D). E, F. Survival probability of each cohort. Statistical significance determined via Log-rank test.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Supplementary Figure S4 from Glycoprotein Mucin 13 Expression as a Theranostic Target in Colorectal Cancer
- Date Crossref
- 14/08/2026
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.